Compare FAF & IBRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FAF | IBRX |
|---|---|---|
| Founded | 1889 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Specialty Insurers | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.3B | 6.1B |
| IPO Year | 2009 | 2015 |
| Metric | FAF | IBRX |
|---|---|---|
| Price | $70.35 | $10.39 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 5 |
| Target Price | ★ $77.67 | $12.60 |
| AVG Volume (30 Days) | 1.0M | ★ 31.1M |
| Earning Date | 05-14-2026 | 05-18-2026 |
| Dividend Yield | ★ 3.14% | N/A |
| EPS Growth | ★ 376.19 | 38.71 |
| EPS | ★ 6.00 | N/A |
| Revenue | ★ $7,452,200,000.00 | $113,288,000.00 |
| Revenue This Year | $6.36 | $93.25 |
| Revenue Next Year | $5.22 | $149.39 |
| P/E Ratio | $11.70 | ★ N/A |
| Revenue Growth | 21.61 | ★ 668.31 |
| 52 Week Low | $53.95 | $1.83 |
| 52 Week High | $70.27 | $12.43 |
| Indicator | FAF | IBRX |
|---|---|---|
| Relative Strength Index (RSI) | 66.29 | 68.35 |
| Support Level | $64.27 | $2.23 |
| Resistance Level | N/A | N/A |
| Average True Range (ATR) | 1.98 | 1.29 |
| MACD | 0.28 | 0.16 |
| Stochastic Oscillator | 85.73 | 68.08 |
First American Financial Corp is a financial services business providing insurance through segments: Title insurance and related services segment include real estate insurance, property closing services, third-party handling of real estate funds (escrow), risk mitigation, real estate data products, and related real estate transaction services; The home warranty segment provides residential service contracts that cover residential systems, such as heating and air conditioning systems, and certain appliances against failures that occur as the result of normal usage during the coverage period; and The corporate segment includes investments in venture-stage companies, certain financing facilities and corporate services supporting the company's business operations.
ImmunityBio Inc is an integrated clinical-stage biotechnology company discovering, developing, and commercializing next-generation immuno- and cellular therapies that bolster the natural immune system to drive and sustain an immune response. Its platforms for the development of biologic product candidates include (i) antibody-cytokine fusion proteins, (ii) DNA, RNA, and recombinant protein vaccines, and (iii) cell therapies. Its focus includes bladder, lung, and colorectal cancers and GBM and its product candidate Anktiva is an IL-15 superagonist antibody-cytokine fusion protein. It has two geographical segments: the United States and Europe. Key revenue is generated from the United States.